Group 1 - Company announced that its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the launch of HR20031 tablets, which is China's first self-developed oral hypoglycemic combination fixed-dose formulation [1] - HR20031 tablets consist of three active ingredients: Prandial Glucose Regulators, Regaglitin, and Metformin, and are intended for adult patients with type 2 diabetes who have inadequate blood sugar control after Metformin treatment [2] - The product aims to simplify the treatment regimen by reducing the number of medications taken, thereby improving patient adherence to therapy [2] Group 2 - Diabetes has become the third most serious chronic disease affecting human health, with a prevalence rate of 13.79% among adults in China, translating to approximately 148 million patients [2] - The blood sugar control rate among type 2 diabetes patients is only 50.1%, indicating a significant need for effective treatment options [2] - The total research and development investment for HR20031 tablets has reached approximately 189.24 million yuan [2]